Biologics Safety: Stronger Pharmacovigilance For First-In-Class BLAs Urged In JAMA Report

Over 23 percent of biologics were subject to post-approval “Dear Doctor” communications or black box warnings during a 12-year period, study finds.

More from Archive

More from Pink Sheet